Haemonetics (HAE) reported $1.3B in revenue for fiscal 2025, −2.0% year on year. That ranks #1591 by revenue among 2853 SEC filers and #147 in Healthcare. Net income was $97,308, a net margin of 0.0%. Revenue has grown 4.4% a year on average since 2011 ($728M then). The fiscal 2025 balance sheet shows $2.5B in total assets, $363M in cash and $920M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.3B | −2.0% | FY20252026-03-28 |
| Gross profitGrossProfit | $788M | +5.2% | FY20252026-03-28 |
| Operating incomeOperatingIncomeLoss | $157M | −29.3% | FY20252026-03-28 |
| Net incomeNetIncomeLoss | $97,308 | −42.0% | FY20252026-03-28 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $293M | +61.4% | FY20252026-03-28 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $32.8M | −16.5% | FY20252026-03-28 |
| Total assetsAssets | $2.5B | −1.6% | FY20252025-12-27 |
| Shareholders' equityStockholdersEquity | $911M | +0.5% | FY20252025-12-27 |
| CashCashAndCashEquivalentsAtCarryingValue | $363M | +13.3% | FY20252025-12-27 |
| Long-term debtLongTermDebtNoncurrent | $920M | −24.6% | FY20252025-12-27 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q2 20262026-06-27 | $339M | $33.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 122 of 161 companies compared | 0.0% | |
| Operating marginRank 80 of 160 companies compared | 11.7% | |
| R&D as share of revenueRank 78 of 102 companies compared | 4.5% | |
| Cash as share of revenueRank 29 of 160 companies compared | 27.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Haemonetics Corp
- Ticker
- HAE
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 04-03
- CIK
- 0000313143
Filings
- 10-QAug 6, 2026Open filing →
- 10-KMay 20, 2026Open filing →
- 10-QFeb 5, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| LivanovaLIVN | $1.4B | −$243M |
| ConmedCNMD | $1.4B | $47.1M |
| Stevanato GroupSTVN | $1.3B | $158M |
| HaemoneticsHAE | $1.3B | $97,308 |
| Phibro Animal HealthPAHC | $1.3B | $48.3M |
| ProgynyPGNY | $1.3B | $58.5M |
| Curaleaf HoldingsCURLF | $1.3B | −$231M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Haemonetics — Key figures |url=https://companiesranked.com/en/company/haemonetics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Haemonetics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/haemoneticsBibTeX
@misc{companiesranked-en-company-haemonetics-2026,
author = {{CompaniesRanked}},
title = {{Haemonetics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/haemonetics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000313143-26-000050 · May 20, 2026
{{cite web |title=Haemonetics — Key figures — 10-K (0000313143-26-000050) |url=https://www.sec.gov/Archives/edgar/data/313143/000031314326000050/hae-20260328.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-05-20}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.